Worse Outcomes for Head and Neck Rhabdomyosarcoma Secondary to Reduced-dose Cyclophosphamide

Efforts to reduce late morbidity in head and neck rhabdomyosarcoma include proton therapy and reduced-doses of cyclophosphamide. We show that both the dose-intensity and cumulative cyclophosphamide dose seem to play a significant role in achieving local control for patients with head and neck rhabdomyosarcoma treated with definitive irradiation using either photons or protons.

https://ift.tt/2Rs8YFY